High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: Treatment description and preliminary results of a phase I/II clinical trial
High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: Treatment description and preliminary results of a phase I/II clinical trial
复制标题
DOI：
10.1016/s0360-3016(00)00687-8
复制
发表时间：
2000-10-01
影响因子：
7
通讯作者：
Inoue, T
中科院分区：
文献类型：
--
作者：
Yoshioka, Y;Nose, T;Inoue, T
目的：为了改善结果为局限性前列腺癌，超分割铱-192高剂量率（HDR）近距离放射治疗作为一个单一疗法的前瞻性临床试验initiated.Methods和Materials：1995年5月至1998年9月，22植入物进行了22例局限性前列腺癌（T1：T2：T3：T4 = 4：6：9：3）在大坂大学医院。19名患有T3-T4肿瘤或治疗前PSA大于或等于20.0 ng/mL的患者接受了激素治疗。没有患者接受外部射束辐射。使用实时超声引导进行经会阴针植入，然后进行剂量优化程序。患者每天照射2次，间隔时间大于6 h。总剂量为48戈伊/8次/5天或54戈伊/9次/5天。使用放射治疗肿瘤学组（RTOG）放射发病率评分标准对急性毒性进行评分。中位随访时间为31 months.Results：HDR近距离放射治疗作为单一疗法耐受性良好。未发生明显的术中或围手术期并发症。无患者发生3级或以上急性毒性。PSA水平在95%的患者在照射后20个月内恢复正常。四年临床和生化无复发率分别为95%和55%.Conclusion：急性毒性与此方法是可以接受的。进一步的患者累积和更长的随访将允许与其他技术进行比较。(C)2000 Elsevier Science Inc.
Purpose: To improve results for localized prostate cancer, a prospective clinical trial of hyperfractionated Iridium-192 high-dose-rate (HDR) brachytherapy as a monotherapy was initiated.Methods and Materials: Between May 1995 and September 1998, 22 implants were performed on 22 patients with localized prostate cancer (T1:T2:T3:T4 = 4:6:9:3) at Osaka University Hospital. Nineteen patients, who had T3-T4 tumors or pretreatment PSA greater than or equal to 20.0 ng/mL, received hormone therapy. No patient had external beam radiation. Transperineal needle implants using real-time ultrasound guidance were performed, followed by dose optimization program. Patients were irradiated twice a day, with a time interval of more than 6 h. Total dose was 48 Gy/8 fractions/5 days or 54 Gy/9 fractions/5 days. Acute toxicity was scored using the Radiation Therapy Oncology Group (RTOG) radiation morbidity scoring criteria. Median follow-up time was 31 months.Results: HDR brachytherapy as a monotherapy was well-tolerated. No significant intra- or peri-operative complications occurred. No patient experienced acute toxicity of grade 3 or more. PSA levels normalized in 95% of patients within 20 months after irradiation. Four-year clinical and biochemical relapse-free rates were 95% and 55%, respectively.Conclusion: Acute toxicity with this method was acceptable. Further patient accrual and longer follow-up will allow comparison to other techniques. (C) 2000 Elsevier Science Inc.